IDEAYA Biosciences's Q2 net loss widens as costs mount

IDEAYA Biosciences

05/08/2025 11:17

Overview

IDEAYA reports Q2 net loss of $77.5 mln, vs $72.2 mln year-ago, driven by higher R&D expenses

Co has ~$992 mln cash, expected to fund operations into 2029

Phase 2/3 trial for darovasertib on track for median PFS data by year-end

Outlook

IDEAYA expects median PFS data for darovasertib by year-end 2025

Company plans three IND submissions by year-end 2025

IDEAYA anticipates cash to fund operations into 2029

Result Drivers

CLINICAL TRIAL EXPANSION - Increased R&D expenses driven by expansion of clinical trials, including darovasertib and crizotinib combination in metastatic uveal melanoma

ORGANIZATIONAL GROWTH - Higher G&A expenses attributed to scaling efforts for potential U.S. launch of darovasertib

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.88
Q2 Net Income
-$77.49 mln
Q2 Operating Expenses
$88.81 mln
Q2 Profit From Operations
-$88.81 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for IDEAYA Biosciences Inc is $47.00, about 46.8% above its August 4 closing price of $25.00

Press Release: ID:nPn4jXCWRa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)